Biotech has always been a little unconventional, but, as the industry’s bear market drags on, efforts to stay afloat are ...

In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

Arialys Therapeutics' precision medicine has shown preclinical potential to address the underlying cause of anti-NMDA ...

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...

BMS didn’t want to choose between clinical expertise and financial know-how when selecting a new strategy leader. The Big ...

The FDA has stopped new clinical trials that export American citizens’ living cells from the U.S. to “China and other hostile ...

Life sciences investment firm Syncona has blamed the “particularly challenging” market conditions for shifting its strategy ...

Multiple developers of connected diabetes hardware have announced plans this week to link their insulin pumps with continuous ...

The miniaturized surgical robot maker Virtual Incision has pinched a new CEO, as it aims to expand its commercial reach ...

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...

The FDA is introducing a new priority voucher program designed to shorten the drug review process from 10 to 12 months down ...

KalVista Pharmaceuticals has become the latest biotech to face delays to the FDA’s decision-making, as the agency apparently ...